Managing the adverse effects of nonsteroidal anti-inflammatory drugs

References

• Burke A, Smyth E, FitzGerald GA. Analgesic-antipyretic agents: pharmacotherapy of gout. In: Goodman & Gilman’s the pharmacological basis of therapeutics (11th Edition). Brunton LL, Lazo JS, Parker KL (Eds). McGraw-Hill, NY, USA 673–715 (2006).
   Google Scholar
• FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med.345, 433–442 (2001).
   PubMed Web of Science ®Google Scholar
• Massó González EL, Patrignani P, Tacconelli S, Rodríguez LA. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthritis Rheum.62, 1592–1601 (2010).
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol.52, 1628–1636 (2008).
   PubMed Web of Science ®Google Scholar
• Bueno H, Bardají A, Patrignani P, Martín-Merino E, García-Rodríguez LA. Spanish case-control study to assess NSAID-associated ACS risk investigators. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am. J. Cardiol.105, 1102–1106 (2010).
   PubMed Web of Science ®Google Scholar
• Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science294(5548), 1871–1875 (2001).
   PubMed Web of Science ®Google Scholar
• Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J. Lipid Res.50, S423–S428 (2009).
   PubMed Web of Science ®Google Scholar
• Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res.50, S237–S242 (2009).
   PubMed Web of Science ®Google Scholar
• Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J. Lipid Res.50, S29–S34 (2009).
   PubMed Web of Science ®Google Scholar
• Kulmacz RJ, van der Donk WA, Tsai AL. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog. Lipid Res.42(5), 377–404 (2003).
   PubMed Web of Science ®Google Scholar
• Harper KA, Tyson-Capper AJ. Complexity of COX-2 gene regulation. Biochem. Soc. Trans.36, 543–545 (2008).
   PubMed Web of Science ®Google Scholar
• Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology136(5), 1669–1679 (2009).
   PubMed Web of Science ®Google Scholar
• Simmons L, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev.56, 387–437 (2004).
   PubMed Web of Science ®Google Scholar
• Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest.108(1), 7–13 (2001).
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat.82(1–4), 85–94 (2007).
   PubMed Web of Science ®Google Scholar
• Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ329(7478), 1317 (2004).
   PubMed Web of Science ®Google Scholar
• Luqmani R, Hennell S, Estrach C et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology45, 1167–1169 (2006).
   PubMed Web of Science ®Google Scholar
• Patrignani P, Panara MR, Greco A et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther.271, 1705–1721 (1994).
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pinca E et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res.17, 317–327 (1980).
   PubMed Web of Science ®Google Scholar
• Patrignani P, Tacconelli S, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. Ther. Clin. Risk Manag.4(5), 983–997 (2008).
   PubMedGoogle Scholar
• Wallace JL, Chin BC. Inflammatory mediators in gastrointestinal defense and injury. Proc. Soc. Exp. Biol. Med.214(3), 192–203 (1997).
   PubMedGoogle Scholar
• Silen W, Ito S. Mechanisms for rapid re-epithelialization of the gastric mucosal surface. Annu. Rev. Physiol.47, 217–229 (1985).
   PubMed Web of Science ®Google Scholar
• Tarnawski A, Szabo IL, Husain SS, Soreghan B. Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J. Physiol. Paris.95(1–6), 337–344 (2001).
   PubMedGoogle Scholar
• Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc. Natl Acad. Sci. USA98(11), 6470–6475 (2001).
   PubMed Web of Science ®Google Scholar
• Somasundaram S, Sigthorsson G, Simpson RJ et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment. Pharmacol. Ther.14(5), 639–650 (2000).
   PubMed Web of Science ®Google Scholar
• FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov.2, 879–890 (2003).
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med.343(21), 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) reduction in ulcer complications: randomised controlled trial. Lancet364, 665–674 (2004).
   PubMed Web of Science ®Google Scholar
• Kargman S, Charleson S, Cartwright M et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology111, 445–454 (1996).
   PubMed Web of Science ®Google Scholar
• Shigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J. Pharmacol. Exp. Ther.286, 1383–1390 (1998).
   PubMed Web of Science ®Google Scholar
• Schmassmann A, Zoidl G, Peskar BM et al. Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol.290, G747–G756 (2006).
   PubMed Web of Science ®Google Scholar
• Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology112, 387–397 (1997).
   PubMed Web of Science ®Google Scholar
• Takahashi S, Shigeta J, Inoue H, Tanabe T, Okabe S. Localization ofcyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am. J. Physiol.275, G1137–G1145 (1998).
   Google Scholar
• Tanaka A, Araki H, Komoike Y, Hase S, Takeuchi K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J. Physiol. Paris95(1–6), 21–27 (2001).
   PubMed Web of Science ®Google Scholar
• Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr. Med. Res. Opin.23(1), 163–173 (2007).
   PubMed Web of Science ®Google Scholar
• Konturek PC, Kania J, Burnat G, Hahn EG, Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J. Physiol. Pharmacol.56(5), 57–73 (2005).
   PubMed Web of Science ®Google Scholar
• Gana TJ, Huhlewych R, Koo J. Focal gastric mucosal blood flow in aspirin-induced ulceration. Ann. Surg.205(4), 399–403 (1987).
   PubMed Web of Science ®Google Scholar
• Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology119(3), 706–714 (2000).
   PubMed Web of Science ®Google Scholar
• Wallace JL, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol. Sci.15(11), 405–406 (1994).
   PubMed Web of Science ®Google Scholar
• Asako H, Kubes P, Wallace J, Wolf RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology103(1), 146–152 (1992).
   PubMed Web of Science ®Google Scholar
• Asako H, Kubes P, Wallace J, Gaginella T, Wolf RE, Granger DN. Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am. J. Physiol.262(5 Pt 1), G903–G908 (1992).
   PubMed Web of Science ®Google Scholar
• Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am. J. Physiol.259(3 Pt 1), G462–G467 (1990).
   PubMed Web of Science ®Google Scholar
• Wallace JL, McKnight W, Miyasaka M et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am. J. Physiol.265(5 Pt 1), G993–G998 (1993).
   Google Scholar
• Wallace JL, Arfors KE, McKnight GW. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology100(4), 878–883 (1991).
   PubMed Web of Science ®Google Scholar
• Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol.61(6), 631–637 (2001).
   PubMed Web of Science ®Google Scholar
• Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am. J. Med.86(4), 449–458 (1989).
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Hocking MP, Maico DG, McGuigan JE. Effects of antibodies to gastric inhibitory peptide on gastric acid secretion and gastrin release in the dog. Gastroenterology84(5 Pt 1), 81941–81983 (1983).
   Google Scholar
• Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch. Intern. Med.147(1), 85–88 (1987).
   PubMedGoogle Scholar
• Minocha A and Greenbaum DS. Pill-esophagitis caused by nonsteroidal antiinflammatory drugs. Am. J. Gastroenterol.86(8), 1086–1089 (1991).
   PubMedGoogle Scholar
• Kim SL, Hunter JG, Wo JM, Davis LP, Waring JP. NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? J. Clin. Gastroenterol.29(1), 32–34 (1999).
   PubMedGoogle Scholar
• Lanas AI, Sousa FL, Ortego J, Esteva F, Blas JM, Soria J, Sáinz R. Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur. J. Gastroenterol. Hepatol.7(11), 1065–1072 (1995).
   PubMedGoogle Scholar
• Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu. Rev. Physiol.57, 565–583 (1995).
   PubMed Web of Science ®Google Scholar
• Atherton C, Jones J, McKaig B et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin. Gastroenterol. Hepatol.2, 113–120 (2004).
   PubMed Web of Science ®Google Scholar
• Twiss IM, Burggraaf J, Schoemaker RC et al. The sugar absorption test in the evaluation of the gastrointestinal intolerant to bisphosphonates: studies with oral pamidronate. Clin. Pharmacol. Ther.69, 431–437 (2001).
   PubMedGoogle Scholar
• Sigthorsson G, Crane R, Simon T et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut47, 527–532 (2000).
   PubMed Web of Science ®Google Scholar
• Smecuol E, Bai JC, Sugai E et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut49, 650–655 (2001).
   PubMed Web of Science ®Google Scholar
• Day JP, Lanas A, Rustagi P et al. Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. J. Clin. Gastroenterol.22, 96–103 (1996).
   PubMedGoogle Scholar
• Smecuol E, Pinto MI, Suarez A et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin. Gastroenterol. Hepatol.7(5), 524–529 (2009).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Eisen GM, Lewis B et al. Video capsule endoscopy to prospectively assesses small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroenterol. Hepatol.3(2), 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Patrono C, Baigent C, Hirsh J and Roth G. American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133, 199S–233S (2008).
   PubMed Web of Science ®Google Scholar
• Minuz P, Gaino S, Zuliani V et al. Functional role of p38 mitogen activated protein kinase in platelet activation induced by a thromboxane A2 analogue and by 8-iso-prostaglandin F2a. Thromb. Haemost.87, 888–898 (2002).
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Rodriguez LG, Patrignani P. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacol. Rep.62(3), 530–535 (2010).
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest.116, 4–15 (2006).
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) trial investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med.352(11), 1092–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352(11), 1071–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J et al. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ332, 1302–1308 (2006).
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ342, c7086 (2011).
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, McAdam B, Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther.289, 735–741 (1999).
   PubMed Web of Science ®Google Scholar
• Stitham J, Arehart EJ, Gleim SR, Douville KL, Hwa J. Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediat.82, 95–108 (2007).
   PubMed Web of Science ®Google Scholar
• Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood69, 180–186 (1987).
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Sciulli MG et al. Human pharmacology of naproxen sodium. J. Pharmacol. Exp. Ther.322, 453– 460 (2007).
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Sciulli MG et al. Clinical pharmacology of platelet monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation109, 1468–1471 (2004).
   PubMed Web of Science ®Google Scholar
• Singh R, Kumar R, Singh DP. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: gastrointestinal-sparing potential drugs. J. Med. Food.12(1), 208–218 (2009).
   PubMedGoogle Scholar
• Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol.147, S193–S201 (2006).
   PubMed Web of Science ®Google Scholar
• Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res. Ther.10(2), S4 (2008).
   PubMedGoogle Scholar
• White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am. J. Cardiol.104(6), 840–845 (2009).
   PubMed Web of Science ®Google Scholar
• Moore A, Bjarnason I, Cryer B et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin. Gastroenterol. Hepatol.7(11), 1156–1163 (2009).
   PubMed Web of Science ®Google Scholar
• Cullen D, Bardhan KD, Eisner M et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment. Pharmacol. Ther.12(2), 135–140 (1998).
   PubMed Web of Science ®Google Scholar
• Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum.50(8), 2433–2440 (2004).
   PubMed Web of Science ®Google Scholar
• Laine L, Bombardier C, Hawkey CJ et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology123(4), 1006–1012 (2002).
   PubMed Web of Science ®Google Scholar
• Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet343(8905), 1075–1078 (1994).
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Field TS, Harrold LR et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA289, 1107–1116 (2003).
   PubMed Web of Science ®Google Scholar
• Pilotto A, Franceschi M, Vitale D, Zaninelli A, Masotti G, Rengo F. Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms. Eur. J. Clin. Pharmacol.62, 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA284, 1247–1255 (2000).
   PubMed Web of Science ®Google Scholar
• Baron JA, Sandler RS, Bresalier RS et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet372(9651), 1756–1764 (2008).
   PubMed Web of Science ®Google Scholar
• Lanas A, Hirschowitz BI. Toxicity of NSAIDs in the stomach and duodenum. Eur. J. Gastroenterol. Hepatol.11(4), 375–381 (1999).
   PubMedGoogle Scholar
• Garcia Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res.3(2), 98–101 (2001).
   PubMedGoogle Scholar
• Rostom A, Dube C, Wells G et al. Prevention of NSAID induced gastroduodenal ulcers. Cochrane Database Syst. Rev.4, 1–111 (2004).
   Google Scholar
• Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.123, 241–249 (1995).
   PubMed Web of Science ®Google Scholar
• Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam. Med.28(3), 204–210 (1996).
   PubMedGoogle Scholar
• Taha AS, Hudson N, Hawkey CJ et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N. Engl. J. Med.334(22), 1435–1439 (1996).
   PubMed Web of Science ®Google Scholar
• Hooper L, Brown TJ, Elliott R et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ329, 948–957 (2004).
   PubMed Web of Science ®Google Scholar
• Rostom A, Dubé C, Jolicoeur E, Boucher M, Joyce J. Gastro-duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Technology report no 38. Canadian Coordinating Office for Health Technology Assessment, Ottawa, Canada (2003).
   Google Scholar
• Pérez-Aisa MA, Del Pino D, Siles M, Lanas A. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment. Pharmacol. Ther.21(1), 65–72 (2005).
   PubMed Web of Science ®Google Scholar
• Graham DY, Agrawal NM, Campbell DR et al. NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch. Intern. Med.162(2), 169–175 (2002).
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) study group. N. Engl. J. Med.338, 727–734 (1998).
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) study group. N. Engl. J. Med.338, 719–726 (1998).
   PubMed Web of Science ®Google Scholar
• Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med.344, 967–973 (2001).
   PubMed Web of Science ®Google Scholar
• Lanas A, García-Rodríguez LA, Arroyo MT et al. Investigators of the Asociación Española de Gastroenterología (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol.102(3), 507–515 (2007).
   PubMed Web of Science ®Google Scholar
• Lanas A, Bajador E, Serrano P et al. Nitrovasodilators, lowdose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med.343, 834–839 (2000).
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology132(2), 498–506 (2007).
   PubMed Web of Science ®Google Scholar
• Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA292(16), 1955–1960 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham R, Dalea B, Undyb B, Gaunta N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J. Hosp. Infect.54(3), 243–245 (2003).
   PubMed Web of Science ®Google Scholar
• Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am. J. Gastroenterol.103(9), 2308–2313 (2008).
   PubMed Web of Science ®Google Scholar
• Pant C, Madonia P, Minocha A. Does PPI therapy predispose to Clostridium difficile infection? Nat. Rev. Gastroenterol. Hepatol.6(9), 555–557 (2009).
   PubMed Web of Science ®Google Scholar
• Chiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case–control study. Pharmacoepidemiol. Drug Saf.19(11), 1131–1136 (2010).
   PubMedGoogle Scholar
• Pouwels S, Lalmohamed A, Souverein P et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos. Int.22(3), 903–910 (2011).
   PubMed Web of Science ®Google Scholar
• Laine L. Proton pump inhibitors and bone fractures? Am. J. Gastroenterol.104(2), S21–S26 (2009).
   Google Scholar
• Geller JL, Adams JS. Proton pump inhibitor therapy and hip fracture risk. JAMA297(13), 1429–1430 (2007).
   PubMedGoogle Scholar
• Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA301(9), 937–944 (2009).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med.363(20), 1909–1917 (2010).
   PubMed Web of Science ®Google Scholar
• Rostom A, Muir K, Dubé C et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin. Gastroenterol. Hepatol.5(7), 818–828 (2007).
   PubMed Web of Science ®Google Scholar
• Hunt RH, Harper S, Callegari P et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol. Ther.17(2), 201–210 (2003).
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res. Ther.10(2), S3 (2008).
   PubMedGoogle Scholar
• Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N. Engl. J. Med.347(26), 2104–2110 (2002).
   PubMed Web of Science ®Google Scholar
• Lai KC, Chu KM, Hui WM et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am. J. Med.118(11), 1271–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Chan FK, Wong VW, Suen BY et al. Proton pump inhibitor plus a COX-2 inhibitor for the prevention of recurrent ulcer bleeding in patients with arthritis: a double blinded, randomized trial. Gastroenterology130, A105 (2006).
   Google Scholar
• Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment. Pharmacol. Ther.20, 321–331 (2004).
   PubMedGoogle Scholar
• Latimer N, Lord J, Grant RL, O’Mahony R, Dickson J, Conaghan PG. National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ339, b2538 (2009).
   Google Scholar
• Lanas A, García-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med.14(9), 38 (2011).
   Google Scholar
• Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol. Ther.18(11–12), 1137–1147 (2003).
   PubMed Web of Science ®Google Scholar
• Van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol. Ther.26(2), 265–275 (2007).
   PubMed Web of Science ®Google Scholar
• Abraham NS, El-Serag HB, Johnson ML et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology129(4), 1171–1178 (2005).
   PubMed Web of Science ®Google Scholar
• Chan FK. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf.28(4), 287–300 (2005).
   PubMedGoogle Scholar
• Huang JQ, Sridhar L, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatoryndrugs in peptic-ulcer disease: a meta-analysis. Lancet359, 14–22 (2002).
   PubMed Web of Science ®Google Scholar
• Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting longterm treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet359, 9–13 (2002).
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet352, 1016–1021 (1998).
   PubMed Web of Science ®Google Scholar
• Lai KC, Lau CS, Ip WY et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol. Ther.17(6), 799–805 (2003).
   PubMed Web of Science ®Google Scholar
• Taha AS, Angerson WJ, Prasad R, McCloskey C, Blatchford O. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment. Pharmacol. Ther.26(8), 1171–1178 (2007).
   PubMed Web of Science ®Google Scholar
• McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med.119, 624–638 (2006).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol.52(18), 1502–1517 (2008).
   PubMed Web of Science ®Google Scholar
• Ibáñez L, Vidal X, Vendrell L et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol. Ther.23, 235–242 (2006).
   PubMed Web of Science ®Google Scholar
• Lanas A, García Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut55(12), 1731–1738 (2006).
   PubMed Web of Science ®Google Scholar
• Nakashima S, Ota S, Arai S et al. Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. World J. Gastroenterol.15(6), 727–731 (2009).
   PubMedGoogle Scholar
• Taha AS, McCloskey C, Prasad R et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a Phase III, randomised, double-blind, placebo-controlled trial. Lancet374(9684), 119–125 (2009).
   PubMed Web of Science ®Google Scholar
• Ng FH, Wong SY, Lam KF et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology138(1), 82–88 (2010).
   PubMed Web of Science ®Google Scholar
• Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med.346(26), 2033–2038 (2002).
   PubMed Web of Science ®Google Scholar
• Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med.352(3), 238–244 (2005).
   PubMed Web of Science ®Google Scholar
• Lanas A. The appropriate use of proton-pump inhibitor co-therapy with non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors. Aliment Pharmacol. Ther.21(1), 2–4, 21–24 (2005).
   PubMedGoogle Scholar
• Yeomans ND, Lanas A, Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol. Ther.22, 795–801 (2005).
   PubMed Web of Science ®Google Scholar
• Watson DJ, Harper SE, Zhao PL et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch. Intern. Med.160, 2998–3003 (2000).
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res. Ther.7, R644–R665 (2005).
   PubMed Web of Science ®Google Scholar
• Hawkey C, Talley NJ, Yeomans ND. NASA1 SPACE1 Study Group Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am. J. Gastroenterol.100(5), 1028–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Jones RH, Yeomans ND et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol. Ther.25(7), 813–821 (2007).
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am. J. Gastroenterol.101(4), 701–710 (2006).
   PubMed Web of Science ®Google Scholar
• Laine L, Smith R, Min K et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol. Ther.24, 751–767 (2006).
   PubMed Web of Science ®Google Scholar
• Lanas A, García-Rodríguez LA, Polo-Tomás M et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am. J. Gastroenterol.104(7), 1633–1641 (2009).
   PubMed Web of Science ®Google Scholar
• Lanas A, Perez-Aisa MA, Feu F et al. Investigators of the Asociación Española de Gastroenterología (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am. J. Gastroenterol.100(8), 1685–1693 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Eisen GM, Lewis B et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol. Ther.25(10), 1211–1222 (2007).
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet369(9560), 465–473 (2007).
   PubMed Web of Science ®Google Scholar
• Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet376(9736), 173–179 (2010).
   PubMed Web of Science ®Google Scholar
• Laine L, Connors LG, Reicin A et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology124, 288–292 (2003).
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Ell C, Simon B et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin. Gastroenterol. Hepatol.6, 536–544 (2008).
   PubMed Web of Science ®Google Scholar
• Maiden L, Thjodleifsson B, Seigal A et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase–2 selective agents on the small bowel:cross-sectional capsule enteroscopy study. Clin. Gastroenterol.Hepatol.5, 1040–1045 (2007).
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Henry J et al. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res. Ther.10, R7 (2008).
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Jones JI, Atherton CT et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut52(11), 1537–1542 (2003).
   PubMed Web of Science ®Google Scholar
• Niwa Y, Nakamura M, Ohmiya N et al. Efficacy of rebamipide for diclofenac induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J. Gastroenterol.43(4), 270–276 (2008).
   PubMed Web of Science ®Google Scholar
• Sivalingam N, Hanumantharaya R, Faith M et al. Curcumin reduces indomethacin- induced damage in the rat small intestine. J. Appl. Toxicol.27(6), 551–560 (2007).
   PubMed Web of Science ®Google Scholar
• Hayllar J, Smith T, Macpherson A et al. Nonsteroidal antiinflammatory drug induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying antirheumatic drugs. Arthritis Rheum.37, 1146–1150 (1994).
   PubMed Web of Science ®Google Scholar
• Scarpignato C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut57, 145–148 (2008).
   PubMed Web of Science ®Google Scholar
• Lanas A, Scarpignato C. Microbial flora in NSAID induced intestinal damage: a role for antibiotics? Digestion73(1), 36–50 (2006).
   Google Scholar
• Bjarnason I, Hayllar J, Smethurst P et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut33(9), 1204–1208 (1992).
   PubMed Web of Science ®Google Scholar
• Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokineticpharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford)44, 846–859 (2005).
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation115, 1634–1642 (2007).
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med.345, 1809–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Renda G, Tacconelli S, Capone ML et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin. Pharmacol. Ther.80, 264–274 (2006).
   PubMed Web of Science ®Google Scholar
• Anzellotti P, Capone ML, Jeyam A et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis. Rheum.63, 850–859 (2011).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar